Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon Alfa 2B Plus Thalidomide in Resected High-Risk Sarcoma
NCT00026416Phase 2Unknown
- Sponsor
- Herbert Irving Comprehensive Cancer Center
- Start
- Oct 2001
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of interferon alfa-2b and thalidomide in soft tissue sarcoma (STS) and bone sarcoma, sponsored by Herbert Irving Comprehensive Cancer Center. Primary endpoint: Time to Disease Progression. Status: unknown.
02
Drugs
interferon alfa-2bthalidomide
03
Conditions
soft tissue sarcoma (STS)bone sarcoma
Beyond the preview
Go deeper on NCT00026416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00026416.